Immunotherapy Animation: How ASY-77A Targets Cancer Through HSP70
Immunotherapy animation brings complex science to life. We created one for Asylia Therapeutics, a Houston-based biotech company developing novel immune-modulating therapies. Their lead antibody, ASY-77A, enhances antigen presentation to fight cancer. Our animation explains this cutting-edge mechanism in a clear, visual way.
Asylia Therapeutics focuses on a fundamental principle of immunity: antigen presentation. Their work impacts cancer, autoimmune diseases, and infectious diseases — conditions affecting tens of millions of people annually.
The Science Behind This Immunotherapy Animation
The animation centers on HSP70, a protein that controls folding and stability of other proteins. HSP70 plays a key role in immunity. Its function depends on whether it binds ATP or ADP.
When ADP-bound, HSP70 carries tumor antigens to antigen-presenting cells (APCs). The ATP-bound form does not. This distinction is crucial.
In stressed cells — like cancer cells — HSP70 levels increase. The resulting complexes include neoantigens unique to the tumor. These HSP70-antigen complexes leave the tumor and enter the bloodstream. There, they present neoantigens to APCs, helping immune cells recognize and target cancer.
But there’s a problem. Cancer often suppresses the immune system. Effective responses get blocked.
How ASY-77A Works: Visualized Through Immunotherapy Animation
This is where ASY-77A comes in. The antibody binds HSP70-antigen complexes to activate the immune system. Three features make it effective:
1. High affinity binding. ASY-77A binds HSP70 efficiently, even at low doses.
2. Selective targeting. It binds only the ADP-bound form carrying neoantigens — not the empty ATP-bound form.
3. Immune super-complexes. When ASY-77A binds ADP-HSP70, large immune complexes form. These are highly effective at activating the immune system.
The animation shows how these complexes interact with Fc receptors on APCs. This triggers a chain reaction. Cytotoxic CD8 T cells activate and destroy cancer cells.
The result? A personalized patient vaccine. The immune system learns to attack cancer.
Beyond Cancer: Autoimmune Applications
ASY-77A may also treat autoimmune diseases. The animation explains how.
A modification to the Fc region changes its behavior. Instead of activating immunity, it binds inhibitory Fc receptors on APCs. This calms overactive immune responses.
One antibody. Two applications. Cancer and autoimmune diseases.
Why Immunotherapy Animation Matters for Biotech
Immunotherapy is complex. Mechanisms like antigen presentation, Fc receptors, and T cell activation are hard to explain with words alone.
Animation solves this problem:
• Visualizes the invisible. Molecular interactions become clear.
• Simplifies complexity. Multi-step immune cascades are easy to follow.
• Engages stakeholders. Investors, partners, and physicians grasp the science faster.
• Supports communication. One animation works for pitches, conferences, and websites.
Asylia Therapeutics needed to communicate breakthrough science. Animation made it possible.
About Asylia Therapeutics
Asylia Therapeutics develops immune-modulating therapies for cancer, autoimmune diseases, and infectious diseases. Their platform centers on antigen presentation — a fundamental mechanism of immunity.
Their lead antibody, ASY-77A, has produced complete tumor regression in pre-clinical models. This includes solid tumors like breast and colon cancer, and blood cancers like multiple myeloma. Asylia is currently humanizing ASY-77A for first-in-human studies.
Consider Immunotherapy Animation for Your Science
Do you develop antibodies, biologics, or immune therapies? Animation can help you communicate your mechanism of action clearly.
We specialize in life science animation. We translate complex science into compelling visuals.
Get in touch — let’s bring your science to life.
